Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sagent Pharmaceuticals, a specialty pharmaceutical company with a specific emphasis on injectable products, has entered into a development pact with Chongqing Lummy Pharmaceutical.
Subscribe to our email newsletter
China-based Chongqing Lummy is engaged in research, development, manufacture and sale of anti-infective, oncology and nutritional parenteral products.
With this agreement, Sagent intends to strengthen its presence in Chinese market, while Chongqing Lummy expects execute its distribution and marketing capabilities in US market.
Further details of the agreement are not disclosed.
Sagent founder, chairman and CEO Jeffrey Yordon said they look forward to a successful collaboration and their continued growth in regulated markets as well as the Chinese domestic market.